posaconazole posaconazole posaconazole, sold under the brand name noxafil among others, is a triazole antifungal medication. posaconazoleclinical datatrade namesnoxafil, posanol, othersahfs/drugs.commonographmedlineplusa607036license data eu ema: by inn us dailymed: posaconazole us fda: posaconazole pregnancycategory au: b3 routes ofadministrationby mouth, intravenousatc codej02ac04 (who) legal statuslegal status au: s4 (prescription only) ca: ℞-only uk: pom (prescription only) us: ℞-only eu: rx-only pharmacokinetic databioavailabilitylow (8 to 47% oral)protein binding98 to 99%metabolismliver (glucuronidation)elimination half-life16 to 31 hoursexcretionfecal (71–77%) and kidney (13–14%)identifiers iupac name 4-methoxy]phenyl]-1-piperazinyl]phenyl]-2--2,4-dihydro-3h-1,2,4-triazol-3-one cas number171228-49-2 ypubchem cid147912drugbankdb01263 ychemspider130409 yunii6tk1g07bhzkeggd02555 ychebichebi:64355 nchemblchembl1397 ncomptox dashboard (epa)dtxsid6049066 echa infocard100.208.201 chemical and physical dataformulac37h42f2n8o4molar mass700.792 g·mol−13d model (jsmol)interactive image smiles o=c1n(/n=c\n1c2ccc(cc2)n7ccn(c6ccc(occ3c(oc3)(c4ccc(f)cc4f)cn5ncnc5)cc6)cc7)(cc)(o)c inchi inchi=1s/c37h42f2n8o4/c1-3-35(26(2)48)47-36(49)46(25-42-47)31-7-5-29(6-8-31)43-14-16-44(17-15-43)30-9-11-32(12-10-30)50-20-27-19-37(51-21-27,22-45-24-40-23-41-45)33-13-4-28(38)18-34(33)39/h4-13,18,23-27,35,48h,3,14-17,19-22h2,1-2h3/t26-,27?,35-,37-/m0/s1 ykey:ragoypupxakgkh-agdniscasa-n y ny (what is this?) (verify) it was approved for medical use in the united states in september 2006, and is available as a generic medication. medical uses posaconazole is used to treat invasive aspergillus and candida infections. it is also used for the treatment of oropharyngeal candidiasis (opc), including opc refractory to itraconazole and/or fluconazole therapy. it is also used to treat invasive infections by candida, mucor, and aspergillus species in severely immunocompromised patients. clinical evidence for its utility in treatment of invasive disease caused by fusarium species (fusariosis) is limited. it appears to be helpful in a mouse model of naegleriasis. pharmacology pharmacodynamics posaconazole works by disrupting the close packing of acyl chains of phospholipids, impairing the functions of certain membrane-bound enzyme systems such as atpase and enzymes of the electron transport system, thus inhibiting growth of the fungi. it does this by blocking the synthesis of ergosterol by inhibiting of the enzyme lanosterol 14α-demethylase and accumulation of methylated sterol precursors. posaconazole is significantly more potent at inhibiting 14-alpha demethylase than itraconazole. microbiology posaconazole is active against the following microorganisms: candida spp. aspergillus spp. zygomycetes spp. pharmacokinetics posaconazole is absorbed within three to five hours. it is predominantly eliminated through the liver, and has a half-life of about 35 hours. oral administration of posaconazole taken with a high-fat meal exceeds 90% bioavailability and increases the concentration by four times compared to fasting state.